Structure–Property Optimization of a Series of Imidazopyridines for Visceral Leishmaniasis

Leishmaniasis is a collection of diseases caused by more than 20 Leishmania parasite species that manifest as either visceral, cutaneous, or mucocutaneous leishmaniasis. Despite the significant mortality and morbidity associated with leishmaniasis, it remains a neglected tropical disease. Existing t...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:ACS infectious diseases 2023-08, Vol.9 (8), p.1470-1487
Hauptverfasser: Dichiara, Maria, Simpson, Quillon J., Quotadamo, Antonio, Jalani, Hitesh B., Huang, Anson X., Millard, Caroline C., Klug, Dana M., Tse, Edwin G., Todd, Matthew H., Silva, Daniel Gedder, da Silva Emery, Flavio, Carlson, J. Eric, Zheng, Shao-Liang, Vleminckx, Margot, Matheeussen, An, Caljon, Guy, Pollastri, Michael P., Sjö, Peter, Perry, Benjamin, Ferrins, Lori
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Leishmaniasis is a collection of diseases caused by more than 20 Leishmania parasite species that manifest as either visceral, cutaneous, or mucocutaneous leishmaniasis. Despite the significant mortality and morbidity associated with leishmaniasis, it remains a neglected tropical disease. Existing treatments have variable efficacy, significant toxicity, rising resistance, and limited oral bioavailability, which necessitates the development of novel and affordable therapeutics. Here, we report on the continued optimization of a series of imidazopyridines for visceral leishmaniasis and a scaffold hop to a series of substituted 2-(pyridin-2-yl)-6,7-dihydro-5H-pyrrolo­[1,2-a]­imidazoles with improved absorption, distribution, metabolism, and elimination properties.
ISSN:2373-8227
2373-8227
DOI:10.1021/acsinfecdis.3c00040